APA (7th ed.) Citation

R, S., I, P., M, K., F, P., E, V., A, K., . . . L, U. (2014). Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung cancer (Amsterdam, Netherlands), 83(1), 109. https://doi.org/10.1016/j.lungcan.2013.10.006

Chicago Style (17th ed.) Citation

R, Schwab, et al. "Major Partial Response to Crizotinib, a Dual MET/ALK Inhibitor, in a Squamous Cell Lung (SCC) Carcinoma Patient with De Novo C-MET Amplification in the Absence of ALK Rearrangement." Lung Cancer (Amsterdam, Netherlands) 83, no. 1 (2014): 109. https://doi.org/10.1016/j.lungcan.2013.10.006.

MLA (9th ed.) Citation

R, Schwab, et al. "Major Partial Response to Crizotinib, a Dual MET/ALK Inhibitor, in a Squamous Cell Lung (SCC) Carcinoma Patient with De Novo C-MET Amplification in the Absence of ALK Rearrangement." Lung Cancer (Amsterdam, Netherlands), vol. 83, no. 1, 2014, p. 109, https://doi.org/10.1016/j.lungcan.2013.10.006.